Xenon Pharmaceuticals Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
XENE$41.39+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(Expressed in thousands of U.S. dollars except share and per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Collaboration revenue (note 10) | $7,500 | $— | $— |
| Operating expenses: | |||
| Research and development | 300,938 | 210,394 | 167,512 |
| General and administrative | 79,632 | 68,904 | 46,542 |
| Total operating expenses | 380,570 | 279,298 | 214,054 |
| Loss from operations | (373,070) | (279,298) | (214,054) |
| Other income (expense): | |||
| Interest income | 26,828 | 41,943 | 27,620 |
| Unrealized fair value gain on trading securities | — | — | 3,550 |
| Foreign exchange gain (loss) | 1,348 | (1,064) | 199 |
| Total other income | 28,176 | 40,879 | 31,369 |
| Loss before income taxes | (344,894) | (238,419) | (182,685) |
| Income tax recovery (expense) (note 14) | (1,016) | 4,089 | 292 |
| Net loss | $(345,910) | $(234,330) | $(182,393) |
| Other comprehensive income (loss): | |||
| Unrealized gain (loss) on available-for-sale securities (note 5) | $1,947 | $(1,535) | $2,923 |
| Comprehensive loss | $(343,963) | $(235,865) | $(179,470) |
| Net loss per common share (note 11): | |||
| Basic and diluted | $(4.36) | $(3.01) | $(2.73) |
| Weighted average common shares outstanding (note 11): | |||
| Basic and diluted | 79,253,751 | 77,894,643 | 66,889,005 |
XENON pharmaceuticals INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.